Trial Profile
A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myelogenous Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs Pevonedistat (Primary) ; Azacitidine; Azacitidine
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Proof of concept; Therapeutic Use
- Sponsors Takeda Oncology
- 10 Aug 2021 Status changed from active, no longer recruiting to completed.
- 07 Aug 2021 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 17 Jun 2021 Results of an exposure-efficacy pooled analysis from three clinical studies: NCT01814826, NCT02782468 and NCT02610777 assessing impact of Pevonedistat exposure on efficacy and safety presented at the 26th Congress of the European Haematology Association